• Novel monoclonal antibody could help revolutionize treatment of children with high-risk neuroblastoma

    1 month ago - By News Medical

    Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children's Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology.
    Read more ...